Roche's IMpower133 offers a glimpse at rare progress in fight against small cell lung cancer
Last summer Roche’s big R&D group at Genentech heralded a breakthrough with positive survival and disease progression data for its frontline study of its checkpoint contender Tecentriq in small cell lung cancer — with landmark results for a field that had long stymied investigators.
Today, the pharma giant spelled out its specific gains from IMpower133, setting a mark at the World Conference on Lung Cancer that others can start to shoot at.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.